Recently, molecular therapeutics targeting receptor tyrosine kinase (RTK) aberrations in lung cancer, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and immunotherapies have been developed.1 Here, ALK is linked to lung cancer.